ELVIRA DEOLINDA RODRIGUES PEREIRA VELLOSO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
21 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 21
- Patterns and Prognostic Impact of CNS Infiltration in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia(2022) PERRUSO, Luiza Lapolla; VELLOSO, Elvira; ROCHA, Vanderson; REGO, Eduardo M.; SILVA, Wellington F.
- Venetoclax and Azacytidine Therapy in High-Risk Myelodysplastic Syndromes: A Retrospective Evaluation of a RealWorld Experience. Latin-American MDS Group - Glam(2022) IASTREBNER, Marcelo; CRISP, Renee Leonor; OVILLA, Roberto; LEON, Andres Gomez-De; PUENTE, Adriana Karola; DUARTE, Fernando Barroso; VELLOSO, Elvira D. R. P.; GUSMAO, Breno; VARELA, Ana; BOADA, Matilde; GRILLE, Sofia
- Part 5: Myelodysplastic syndromes—Treatment of high-risk disease(2018) MAGALHÃES, Silvia Maria Meira; CHAUFFAILLE, Maria de Lourdes Lopes Ferrari; VELLOSO, Elvira Deolinda Rodrigues Pereira; BUZZINI, Renata; BERNARDO, Wanderley Marques
- Myelodysplastic Syndromes in Latin-America - Results from a Novel International Registry: Re-Glam(2022) GRILLE, Sofia; VELLOSO, Elvira D. R. P.; BOADA, Matilde; CHAVEZ, Elia Apodaca; LEON, Andres Gomez-De; RODRIGUEZ-ZUNIGA, Anna Cecilia; MORENO, Emmanuel Martinez; PEREZ-JACOBO, Fernando; ALFONSO, Graciela; SERRANO, Juan Carlos; TEJEIRA, Natalia; DIAZ, Lilian; OLIVARES, Valentina; KORNBLIHTT, Laura; SCHUSTERSCHITZ, Sergio; IASTREBNER, Marcelo
- Splenic Diffuse Red Pulp Small B Cell Lymphoma: Transformation To Diffuse Large Cells B Lymphoma(2013) BEZERRA, Evandro Dantas; FONTENELE, Leila Patricia; PEREIRA, Juliana; LAGE, Luis Alberto de Padua Covas; MACIEL, Felipe; BARQUINERO, Leticia; CARVALHO, Priscila R.; SIQUEIRA, Scheila; VELLOSO, Elvira R. P.
- Paper Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis(2023) SILVA, Wellington Fernandes da; MENDES, Fernanda Rodrigues; MELO, Raphael da Costa Bandeira de; VELLOSO, Elvira Deolinda Rodrigues Pereira; ROCHA, Vanderson; REGO, Eduardo MagalhaesIntroduction: Invasive fungal infection (IFI) accounts for substantial morbidity during the treatment of acute myeloid leukemia (AML) in adults. Antifungal prophylaxis (AP) is needed during intensive chemotherapy, and posaconazole is not widely available. In this study, we aimed to examine the impact of prophylactic anidulafungin during intensive AML remission induction. Methods: This is a retrospective cohort encompassing newly diagnosed AML adult patients. All subjects received intensive chemotherapy and were divided into three groups: patients who did not receive any AP and patients who received fluconazole (150-400 mg/day) or anidulafungin (100 mg/day). Results: During AML induction, 82 patients did not receive AP, 108 and 14 patients received anidulafungin and fluconazole, respectively. IFI incidence was 27%, classified as possible, probable, and proven in 65, 2 and 33%, respectively. Multivariable analysis showed that lower neutrophil counts are associated with IFI (OR = 2.8), whereas age, genetic classification, and lymphocyte counts were not. To examine the impact of anidulafungin in comparison with 'no AP', a propensity score matching analysis was performed. Use of anidulafungin was not related to less IFI during induction, while neutrophil counts remained significant. Patients under prophylactic anidulafungin received less amphotericin B (p < 0.001) but not voriconazole (p = 0.49). Discussion: To our knowledge, this is the first study addressing the role of anidulafungin during AML induction. Here, the incidence of mold infections did not decrease with AP, suggesting that in a setting with a high incidence of IFI, broad spectrum AP might be more suitable.
- RESULTS OF THE LATIN-AMERICAN REGISTRY OF BONE MARROW TRANSPLANTATION (BMT) IN MYELODYSPLASTIC SYNDROME (MDS)(2017) DUARTE, F.; SANTOS, T. E. J.; FUNKE, V. A. M.; COLTURATO, V. A. R. C.; HAMERSCHLAK, N.; VILELA, N. C. V.; LOPES, L. F.; MACEDO, M. C. M. A.; VIGORITO, A. C.; SOARES, R. D. D. A.; PAZ, A.; STEVENAZZI, M.; DIAZ, L.; NETO, A. E. H. N.; BETTARELLO, G.; GUSMAO, B. M.; SALVINO, M. A.; CALIXTO, R. F.; VELLOSO, E. D. R. P.; LEMES, R. P. G.
- Assessment of Bone Microarchitecture in Patients with Systemic Mastocytosis and its Association with Clinical and Biochemical Parameters of the Disease(2023) FRANCO, Andre S.; MURAI, Igor H.; TAKAYAMA, Liliam; CAPARBO, Valeria F.; MARCHI, Luan L.; VELLOSO, Elvira D. R. P.; PEREIRA, Rosa M. R.Patients with systemic mastocytosis (SM) are at high risk of bone deterioration. However, the evaluation of bone microarchitecture in this disease remains unclear. We aimed to assess bone microarchitecture in patients with SM. This was a cross-sectional study of 21 adult patients with SM conducted in a quaternary referral hospital in Sao Paulo, Brazil. A healthy, age-, weight-, and sex-matched cohort of 63 participants was used to provide reference values for bone microarchitecture, assessed by high resolution peripheral quantitative computed tomography (HR-pQCT). Total volumetric bone mineral density (vBMD), cortical vBMD, and cortical thickness at the radius were significantly lower in the control group compared with the SM group (all P < 0.001). Patients with aggressive SM had significantly lower trabecular number (Tb.N) (P = 0.035) and estimated failure load (F.load) (P = 0.032) at the tibia compared with those with indolent SM. Handgrip strength was significantly higher in patients who had more Tb.N at the radius (rho, 0.46; P = 0.036) and tibia (rho, 0.49; P = 0.002), and lower who had more trabecular separation at the radius (rho, -0.46; P = 0.035) and tibia (rho, -0.52; P = 0.016). Strong and positive associations between F.load (rho, 0.75; P < 0.001) and stiffness (rho, 0.70; P < 0.001) at the radius, and between F.load at the tibia (rho, 0.45; P = 0.038) were observed with handgrip strength. In this cross-sectional study, aggressive SM was more susceptible to bone deterioration compared with indolent SM. In addition, the findings demonstrated that handgrip strength was associated with bone microarchitecture and bone strength.
- Differential diagnosis of bone marrow failure syndromes guided by machine learning(2023) GUTIERREZ-RODRIGUES, Fernanda; MUNGER, Eric; MA, Xiaoyang; GROARKE, Emma M.; TANG, Youbao; PATEL, Bhavisha A.; CATTO, Luiz Fernando B.; CLE, Diego V.; NIEWISCH, Marena R.; ALVES-PAIVA, Raquel M.; DONAIRES, Flavia S.; PINTO, Andre Luiz; BORGES, Gustavo; SANTANA, Barbara A.; MCREYNOLDS, Lisa J.; GIRI, Neelam; ALTINTAS, Burak; FAN, Xing; SHALHOUB, Ruba; SIWY, Christopher M.; DIAMOND, Carrie; RAFFO, Diego Quinones; CRAFT, Kathleen; KAJIGAYA, Sachiko; SUMMERS, Ronald M.; LIU, Paul; CUNNINGHAM, Lea; HICKSTEIN, Dennis D.; DUNBAR, Cynthia E.; PASQUINI, Ricardo; OLIVEIRA, Michel Michels De; VELLOSO, Elvira D. R. P.; ALTER, Blanche P.; SAVAGE, Sharon A.; BONFIM, Carmem; WU, Colin O.; CALADO, Rodrigo T.; YOUNG, Neal S.The choice to postpone treatment while awaiting genetic testing can result in significant delay in definitive therapies in patients with severe pancytopenia. Conversely, the misdiagnosis of inherited bone marrow failure (BMF) can expose patients to ineffectual and expensive therapies, toxic transplant conditioning regimens, and inappropriate use of an affected family member as a stem cell donor. To predict the likelihood of patients having acquired or inherited BMF, we developed a 2-step data-driven machine-learning model using 25 clinical and laboratory variables typically recorded at the initial clinical encounter. For model development, patients were labeled as having acquired or inherited BMF depending on their genomic data. Data sets were unbiasedly clustered, and an ensemble model was trained with cases from the largest cluster of a training cohort (n = 359) and validated with an independent cohort (n = 127). Cluster A, the largest group, was mostly immune or inherited aplastic anemia, whereas cluster B comprised underrepresented BMF phenotypes and was not included in the next step of data modeling because of a small sample size. The ensemble cluster A-specific model was accurate (89%) to predict BMF etiology, correctly predicting inherited and likely immune BMF in 79% and 92% of cases, respectively. Our model represents a practical guide for BMF diagnosis and highlights the importance of clinical and laboratory variables in the initial evaluation, particularly telomere length. Our tool can be potentially used by general hematologists and health care providers not specialized in BMF, and in under-resourced centers, to prioritize patients for genetic testing or for expeditious treatment.
- Part 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion(2018) VELLOSO, Elvira Deolinda Rodrigues Pereira; MAGALHÃES, Silvia Maria Meira; CHAUFFAILLE, Maria de Lourdes Lopes Ferrari; BUZZINI, Renata; BERNARDO, Wanderley Marques
- «
- 1 (current)
- 2
- 3
- »